To determine the efficacy of cancer treatment through the inhibition of the NF-κB pathway, various problems have been found: low efficacy of NF-κB inhibitors in addition to lymphoma and leukemia (121), immunosuppression after long-term systemic administration of these drugs (122) and the appearance of short-term drug resistance (123, 124). Here, NFKB1 is linked to lymphoma.